Persistence Market Research
Research & Development in the diagnostic immunoassay and advancement in blocker used for interference and kits manufacturing which ensure consistent and high performance quality is considered to be one of the key reasons for growing immunoassay interference blocker market. The U.S. spend approximately 2-3% in research & development. The advancement in the new drug discoveries is research and diagnostics biologics attribute to growth of the immunoassay interference blockers market. Immunoassay interference prevalence is adaptable and dependent on antibody interference type depending upon the analyte and assay. However, blocker addition in the patient’s sample does not fully remove protein interference. This can retrain the market of immunoassay interference locker market. The immunoassay interference blocker can be segmented on the basis of product and services such as analyzers, reagents & kits and others. Furthermore, immunoassay interference blocker can be categorize on the basis of applications such as cardiology, oncology, infectious disease and others. Moreover, immunoassay interference blocker can be divided into ELISA, PCR, rapid test, ELISPOT and others. The end user of immunoassay interference blocker are hospitals, diagnostic center, clinical laboratories and others.
The global market for immunoassay interference blocker is segmented on basis of product & service type, technology and end user.
Segmentation by Product & Service Type Analyzers Reagents & Kits Others Segmentation by Application Cardiology Oncology Infectious Disease Others
Immunoassay interference blocker market considered to be the fastest growing market. Moreover, through research it has been observed that ELISA test is more reliable and generate fast results for HIV than nucleic test. For reduction of proteins interference in sample of patient’s treatments measurement of a blocking reagent before and after addition is recommended. Also, if reduction of interference is not showing desirable result then series of blocker or a combination of blockers from different species is recommended. Although different research & development carried out in the field of diagnostic immunoassay. Advancement in blocker for interference considered to be the advantage for growth of immunoassay interference blocker market.
On the basis of geography, the global immunoassay interference blocker market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific excluding China, China and the Middle East & Africa. The North America immunoassay interference blocker market is expected to register the maximum market share in the global market, followed by Europe, due to increasing usage of immunoassay technology in clinical research, improvement in the quality of healthcare expenditure and infrastructure, high adoption of low cost for research and diagnostic purpose. However, Asia Pacific region is expected to grow at the highest CAGR during the forecast period and is projected to be a profitable market for new emerging market players in the immunoassay interference blocker market. However, the market for immunoassay interference blocker in Latin America, and the Middle East and Africa regions are estimated to show fast growth due to rising growth of medical treatment for infectious diseases and rising in diagnostic laboratories in tis regions.
Examples of some of the key players present in the global immunoassay interference blocker market are Roche Diagnostics, Abbott Laboratories Inc., Siemens Healthcare, Becton Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, Meridian Life Science Inc., Sysmex Corporation, Beckman Coulter and others.
The report covers exhaustive analysis on:
Regional analysis includes